asciminib Archives -

Novartis has claimed FDA approval for one of its ‘wild card’ drugs – Scemblix – a first-in-class STAMP

Novartis’ ‘wild card’ drug Scemblix gets FDA nod for leukaemia

https://pharmaphorum.com/news/novartis-wild-card-drug-scemblix-gets-fda-nod-for-leukaemia/

Novartis has revealed that the FDA has accepted its resubmission for cholesterol-lowering drug Leqvio – rejected unexpectedly by

Novartis eyes New Year verdict from FDA on delayed Leqvio

https://pharmaphorum.com/news/novartis-eyes-new-year-verdict-from-fda-on-delayed-leqvio/

A first-in-class STAMP inhibitor developed by Novartis – asciminib – has outperformed a current drug for chronic myeloid

Novartis eyes filings for leukaemia drug asciminib after phase 3 win

https://pharmaphorum.com/news/novartis-eyes-filings-for-leukaemia-drug-asciminib-after-phase-3-win/

asciminib